Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group study

Mace L. Rothenberg, P. Y. Liu, Sharon Wilczynski, William A. Nahhas, Gaye L. Winakur, Caroline S. Jiang, Carol M. Moinpour, Ben Lyons, Geoffrey R. Weiss, James H. Essell, Harriet O. Smith, Maurie Markman, David S. Alberts

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

To assess the activity of vinorelbine in women with recurrent or resistant epithelial ovarian cancer following treatment with platinum and paclitaxel in terms of survival rate at 6 months, objective response rate (in the subset of patients with bidimensionally measurable disease), and health-related quality of life. Seventy-nine evaluable patients with progressive ovarian cancer following platinum and taxane therapy received vinorelbine 30 mg/m2 days 1 and 8 of a 21-day treatment cycle. Six-month survival rate for the entire group was 65% (95% CI: 54-75%) and median survival was 10.1 months (95% CI: 7.7-13.6 months). In the 71 women with measurable disease, 0 complete and 2 partial responses were observed (RR = 3%) (95% CI: 0.3-10%). Patients reported substantial symptom-related distress at baseline, which persisted, but did not worsen, during treatment. Patients also had impaired physical functioning at baseline and this continued to decline during treatment. The 6-month survival rate achieved with salvage vinorelbine is comparable to the results obtained with other salvage therapies in patients with relapsed ovarian cancer. During the initial 10 weeks of treatment, vinorelbine did not appear to be effective in alleviating the symptom-related distress or progressive impairment of physical functioning associated with this disease.

Original languageEnglish (US)
Pages (from-to)506-512
Number of pages7
JournalGynecologic Oncology
Volume95
Issue number3
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Survival Rate
Platinum
Therapeutics
Salvage Therapy
Paclitaxel
vinorelbine
Quality of Life
Survival

Keywords

  • Chemotherapy
  • Ovarian cancer
  • Phase II trial
  • Salvage therapy
  • Vinorelbine

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Rothenberg, M. L., Liu, P. Y., Wilczynski, S., Nahhas, W. A., Winakur, G. L., Jiang, C. S., ... Alberts, D. S. (2004). Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group study. Gynecologic Oncology, 95(3), 506-512. https://doi.org/10.1016/j.ygyno.2004.09.004

Phase II trial of vinorelbine for relapsed ovarian cancer : A Southwest Oncology Group study. / Rothenberg, Mace L.; Liu, P. Y.; Wilczynski, Sharon; Nahhas, William A.; Winakur, Gaye L.; Jiang, Caroline S.; Moinpour, Carol M.; Lyons, Ben; Weiss, Geoffrey R.; Essell, James H.; Smith, Harriet O.; Markman, Maurie; Alberts, David S.

In: Gynecologic Oncology, Vol. 95, No. 3, 12.2004, p. 506-512.

Research output: Contribution to journalArticle

Rothenberg, ML, Liu, PY, Wilczynski, S, Nahhas, WA, Winakur, GL, Jiang, CS, Moinpour, CM, Lyons, B, Weiss, GR, Essell, JH, Smith, HO, Markman, M & Alberts, DS 2004, 'Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group study', Gynecologic Oncology, vol. 95, no. 3, pp. 506-512. https://doi.org/10.1016/j.ygyno.2004.09.004
Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS et al. Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group study. Gynecologic Oncology. 2004 Dec;95(3):506-512. https://doi.org/10.1016/j.ygyno.2004.09.004
Rothenberg, Mace L. ; Liu, P. Y. ; Wilczynski, Sharon ; Nahhas, William A. ; Winakur, Gaye L. ; Jiang, Caroline S. ; Moinpour, Carol M. ; Lyons, Ben ; Weiss, Geoffrey R. ; Essell, James H. ; Smith, Harriet O. ; Markman, Maurie ; Alberts, David S. / Phase II trial of vinorelbine for relapsed ovarian cancer : A Southwest Oncology Group study. In: Gynecologic Oncology. 2004 ; Vol. 95, No. 3. pp. 506-512.
@article{c6ef861cddb447d1b1e6c527e6384137,
title = "Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group study",
abstract = "To assess the activity of vinorelbine in women with recurrent or resistant epithelial ovarian cancer following treatment with platinum and paclitaxel in terms of survival rate at 6 months, objective response rate (in the subset of patients with bidimensionally measurable disease), and health-related quality of life. Seventy-nine evaluable patients with progressive ovarian cancer following platinum and taxane therapy received vinorelbine 30 mg/m2 days 1 and 8 of a 21-day treatment cycle. Six-month survival rate for the entire group was 65{\%} (95{\%} CI: 54-75{\%}) and median survival was 10.1 months (95{\%} CI: 7.7-13.6 months). In the 71 women with measurable disease, 0 complete and 2 partial responses were observed (RR = 3{\%}) (95{\%} CI: 0.3-10{\%}). Patients reported substantial symptom-related distress at baseline, which persisted, but did not worsen, during treatment. Patients also had impaired physical functioning at baseline and this continued to decline during treatment. The 6-month survival rate achieved with salvage vinorelbine is comparable to the results obtained with other salvage therapies in patients with relapsed ovarian cancer. During the initial 10 weeks of treatment, vinorelbine did not appear to be effective in alleviating the symptom-related distress or progressive impairment of physical functioning associated with this disease.",
keywords = "Chemotherapy, Ovarian cancer, Phase II trial, Salvage therapy, Vinorelbine",
author = "Rothenberg, {Mace L.} and Liu, {P. Y.} and Sharon Wilczynski and Nahhas, {William A.} and Winakur, {Gaye L.} and Jiang, {Caroline S.} and Moinpour, {Carol M.} and Ben Lyons and Weiss, {Geoffrey R.} and Essell, {James H.} and Smith, {Harriet O.} and Maurie Markman and Alberts, {David S.}",
year = "2004",
month = "12",
doi = "10.1016/j.ygyno.2004.09.004",
language = "English (US)",
volume = "95",
pages = "506--512",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Phase II trial of vinorelbine for relapsed ovarian cancer

T2 - A Southwest Oncology Group study

AU - Rothenberg, Mace L.

AU - Liu, P. Y.

AU - Wilczynski, Sharon

AU - Nahhas, William A.

AU - Winakur, Gaye L.

AU - Jiang, Caroline S.

AU - Moinpour, Carol M.

AU - Lyons, Ben

AU - Weiss, Geoffrey R.

AU - Essell, James H.

AU - Smith, Harriet O.

AU - Markman, Maurie

AU - Alberts, David S.

PY - 2004/12

Y1 - 2004/12

N2 - To assess the activity of vinorelbine in women with recurrent or resistant epithelial ovarian cancer following treatment with platinum and paclitaxel in terms of survival rate at 6 months, objective response rate (in the subset of patients with bidimensionally measurable disease), and health-related quality of life. Seventy-nine evaluable patients with progressive ovarian cancer following platinum and taxane therapy received vinorelbine 30 mg/m2 days 1 and 8 of a 21-day treatment cycle. Six-month survival rate for the entire group was 65% (95% CI: 54-75%) and median survival was 10.1 months (95% CI: 7.7-13.6 months). In the 71 women with measurable disease, 0 complete and 2 partial responses were observed (RR = 3%) (95% CI: 0.3-10%). Patients reported substantial symptom-related distress at baseline, which persisted, but did not worsen, during treatment. Patients also had impaired physical functioning at baseline and this continued to decline during treatment. The 6-month survival rate achieved with salvage vinorelbine is comparable to the results obtained with other salvage therapies in patients with relapsed ovarian cancer. During the initial 10 weeks of treatment, vinorelbine did not appear to be effective in alleviating the symptom-related distress or progressive impairment of physical functioning associated with this disease.

AB - To assess the activity of vinorelbine in women with recurrent or resistant epithelial ovarian cancer following treatment with platinum and paclitaxel in terms of survival rate at 6 months, objective response rate (in the subset of patients with bidimensionally measurable disease), and health-related quality of life. Seventy-nine evaluable patients with progressive ovarian cancer following platinum and taxane therapy received vinorelbine 30 mg/m2 days 1 and 8 of a 21-day treatment cycle. Six-month survival rate for the entire group was 65% (95% CI: 54-75%) and median survival was 10.1 months (95% CI: 7.7-13.6 months). In the 71 women with measurable disease, 0 complete and 2 partial responses were observed (RR = 3%) (95% CI: 0.3-10%). Patients reported substantial symptom-related distress at baseline, which persisted, but did not worsen, during treatment. Patients also had impaired physical functioning at baseline and this continued to decline during treatment. The 6-month survival rate achieved with salvage vinorelbine is comparable to the results obtained with other salvage therapies in patients with relapsed ovarian cancer. During the initial 10 weeks of treatment, vinorelbine did not appear to be effective in alleviating the symptom-related distress or progressive impairment of physical functioning associated with this disease.

KW - Chemotherapy

KW - Ovarian cancer

KW - Phase II trial

KW - Salvage therapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=9944231080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9944231080&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.09.004

DO - 10.1016/j.ygyno.2004.09.004

M3 - Article

C2 - 15581954

AN - SCOPUS:9944231080

VL - 95

SP - 506

EP - 512

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -